Cathie Wood
ONCE

Cathie Wood’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Cathie Wood’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-129
Closed -$5K – 201
2018
Q4 		$5K Hold
129
– – ﹤0.01% 193
2018
Q3 		$7K Buy
+129
New +$8.82K ﹤0.01% 202

Other funds holding ONCE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Cathie Wood's ONCE Position: Q1 2019 in Review

Cathie Wood sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q1 2019, closing a stake of 129 shares — an estimated $5K sold.

Cathie Wood first reported a position in ONCE in Q3 2018 and held it in 2 quarters. The position peaked at $7K in Q3 2018. 199 funds tracked by Wall St. Rank hold ONCE as of Q1 2019.

  • Cathie Wood reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Cathie Wood sold 129 Spark Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $5K.
  • Cathie Wood first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2018 and held it in 2 quarters.
  • Cathie Wood's Spark Therapeutics, Inc. Common Stock position peaked at $7K in Q3 2018.
  • 199 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q1 2019.

Based on ARK Investment Management's 13F filing for Q1 2019, filed 13 May 2019.